Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Roy S. Herbst

Citation

Annals of Oncology (2015) 26 (suppl_9): 103-106. 10.1093/annonc/mdv528

Authors

R.S.S. Herbst1, F. de Marinis2, J. Jassem3, D.R. Spigel4, G. Shankar5, S. Mocci5, A. Sandler5, A. Lopez-Chavez5, S. Li6, G. Giaccone7

Author affiliations

  • 1 Medical Oncology, Yale University School of Medicine Medical Oncology, 06510 - New Haven/US
  • 2 Thoracic Oncology, Istituto Europeo di Oncologia, Milano/IT
  • 3 Oncology And Radiotherapy, Medical University of Gdansk, 80-211 - Gdansk/PL
  • 4 Lung Cancer Research Program, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 5 Clinical Science, Genentech, Inc., South San Francisco/US
  • 6 Biostatistics, Genentech, Inc., South San Francisco/US
  • 7 Lombardi Comprehensive Cancer Center, Georgetown University, Washington/US
More

Resources

Abstract 1004

Background

Current treatment for advanced non-squamous and squamous NSCLC includes platinum-based doublet chemotherapy (chemo) and cancer immunotherapies targeting the PD-L1/PD-1 pathway. Atezolizumab (atezo; MPDL3280A) is a cancer immunotherapy that targets PD-L1 and inhibits binding to PD-1 and B7.1. In a Phase II study of atezo vs docetaxel, high PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC; TC3 or IC3) in patients (pts) with advanced NSCLC was associated with a median progression free-survival (PFS) of 7.8 mo (95% CI, 4.0-11.5) vs 3.9 mo (95% CI, 1.9-5.7) for docetaxel (Spira, ASCO, 2015). Based on these and other encouraging results and a favorable safety profile, 2 Phase III, multicenter, randomized, open-label studies (IMpower 110 and 111) will evaluate the efficacy and safety of atezo monotherapy compared with platinum-based chemo as first-line therapy for PD-L1–selected chemo-naive pts with advanced NSCLC.

Trial design

These studies will enroll PD-L1–selected (TC3 or IC3) pts with previously untreated stage IV NSCLC (ECOG PS 0-1 and measurable disease per RECIST v1.1; Table). PD-L1 expression will be centrally evaluated using the SP142 IHC assay. Pts with untreated CNS metastases, autoimmune disease or prior immunotherapy will be excluded. Pts will be stratified by sex, ECOG PS, presence of liver metastases at baseline and PD-L1 tumor expression. Pts will be randomized 1:1 to receive atezo (1200 mg) or chemo at standard doses on a 21-day cycle. For both trials, the primary endpoint is investigator-assessed PFS per RECIST v1.1. Secondary endpoints include objective response rate, overall survival, duration of response, safety/tolerability and pharmacokinetics. Mandatory tumor biopsies will be obtained at progression to assess potential biomarkers associated with response and immune escape.

Phase III Atezo Trials

Study Histology N Experimental Arm Comparator Arm Clinical Trials.gov Identifier
IMpower 110 Non-squamous 400 Atezo monotherapy Carboplatin/Cisplatin + Pemetrexed NCT02409342
IMpower 111 Squamous 400 Atezo monotherapy Carboplatin/Cisplatin + Gemcitabine NCT02409355

Clinical trial identification

IMpower 110: GO29431; IMpower 111: GO29432

Disclosure

R.S. Herbst, D.R. Spigel: compensation for consulting from Genentech, Inc. G. Shankar, S. Mocci, A. Sandler, A. Lopez-Chavez, S. Li: employee of Genentech, Inc. G. Giaccone: served on advisory boards for Clovis. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings